Literature DB >> 20919187

Combination chemotherapy.

T A Connors.   

Abstract

Year:  1974        PMID: 20919187      PMCID: PMC1645715     

Source DB:  PubMed          Journal:  Proc R Soc Med        ISSN: 0035-9157


× No keyword cloud information.
  10 in total

Review 1.  DRUG SYNERGISM IN ANTINEOPLASTIC CHEMOTHERAPY.

Authors:  J M VENDITTI; A GOLDIN
Journal:  Adv Chemother       Date:  1964

2.  The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.

Authors:  R J Woodman; A E Sirica; M Gang; I Kline; J M Venditti
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

3.  Interaction of methotrexate and cytosine arabinoside.

Authors:  M H Tattersall; T A Connors; K R Harrap
Journal:  Lancet       Date:  1972-12-23       Impact factor: 79.321

4.  Studies on the mechanism of action of the tumour inhibitory triazenes.

Authors:  R C Audette; T A Connors; H G Mandel; K Merai; W C Ross
Journal:  Biochem Pharmacol       Date:  1973-08-01       Impact factor: 5.858

5.  Increased immunosensitivity in nitrogen mastard-resistant Yoshida sarcoma.

Authors:  S Tsukagoshi; Y Hashimoto
Journal:  Cancer Res       Date:  1973-05       Impact factor: 12.701

6.  Collateral sensitivity of resistant lines of mouse leukemias L1210 and L5178Y.

Authors:  F A Schmid; D J Hutchison
Journal:  Cancer Res       Date:  1972-04       Impact factor: 12.701

7.  Modification of tumor regression by immunologic means.

Authors:  E Mihich
Journal:  Cancer Res       Date:  1969-12       Impact factor: 12.701

8.  Cytidine deaminase and the development of resistance to arabinosyl cytosine.

Authors:  C D Steuart; P J Burke
Journal:  Nat New Biol       Date:  1971-09-22

9.  Antagonism of the anti-tumour effects of asparaginase by methotrexate.

Authors:  T A Connors; M Jones
Journal:  Biochem Pharmacol       Date:  1970-11       Impact factor: 5.858

Review 10.  The emergence of drug resistance in tumours: a characteristic which may be exploited therapeutically.

Authors:  M H Tattersall
Journal:  Br J Cancer       Date:  1973-05       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.